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Introduction
Montanide ISA 51 VG and Montanide ISA 720 VG are
two novel adjuvants dedicated to human therapeutic
vaccines. They have been used in more than 200 clinical
trials involving cancer, AIDS, malaria or autoimmune
disease vaccines and involving an accrual of more than
20000 patients. The adjuvants are rendering stable
water-in-oil emulsions when mixed with water based
antigenic media. Montanide ISA 51 VG is based on a
blend of mannide monooleate surfactant and mineral
oil, whereas Montanide ISA 720 VG uses a non-mineral
oil. Although they have shown preclinical safety, a sur-
vey on clinical environment is performed.
Material and methods
112 published clinical trials with both adjuvants are reviewed
and number of patients per indications are noticed, as well
as the parameters of vaccination such as route of innocu-
laion, volume, antigen dose, or co-stimulating agents. Safety
data obtained are reviewed and are classified according to
their nature, type, and intensity.
Results
Montanide ISA 51 VG was mainly used in cancer and
aids vaccination trials, with an accrual of 6000 patients.
In cancer field the main represented projects are on
melanoma and lung cancer, from clinical Phase I to
Phase IV. Doses can be repeated as up to 10 per year
and per patient, and are mainly given subcutaneously.
Local and general adverse events observed with the vac-
cines are mild to moderate and generally transient, and
refer to headache, local pain or redness at injection site.
Placebo injections do not lead to adverse reactions.
Montanide ISA 720 VG was used in 2000 people,
mainly healthy volunteers of malaria vaccines projects.
Injection is mainly intramuscular, and redness, granulo-
mas or pain are described. This adjuvant was also used
in cancer projects more recently.
Conclusion
Montanide ISA 51 VG and Montanide ISA 720 VG are
novel adjuvants intended to be used in therapeutic vac-
cination programs known to be potent adjuvants indu-
cing CD4 and CD8 responses. This safety review
demonstrates that they are safe and are suitable for
registration by agencies like for NSCLC vaccine in 3
countries
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